Introduction
The angiotensin-converting enzyme (ACE, kininase II, CD143), an important regulator of vascular tone and remodeling, 1,2 is expressed on the luminal surface of endothelial cells of different types of blood vessels. [3] [4] [5] [6] The unique tissue distribution of endothelial ACE, along with preferential expression in lung capillaries, 5, 6 also makes it an almost ideal target for therapy directed toward pulmonary endothelium.
Previous studies from our group demonstrated that monoclonal antibodies directed toward ACE may be highly efficient and specific carriers for the delivery of therapeutic substances (isotopes, proteins, drugs) to the lung vasculature. [7] [8] [9] [10] For example, we have shown that after systemic injection, an anti-ACE monoclonal antibody (designated 9B9) selectively accumulates in the lungs of several mammals, 8, 11 including humans. 10 Furthermore, systemic administration of mAb 9B9 that had been conjugated to the plasminogen activators, catalase or superoxide dismutase, results in the specific targeting and prolonged association of these drugs with the pulmonary vasculature of rats. 12, 13 These conjugates retain biological activity and demonstrate therapeutic effects. For example, rat lung endothelium was protected from injury induced by hydrogen peroxide by the systemic mAb 9B9 conjugated with catalase. 14 This anti-ACE mAb was successfully used to increase selectivity and efficacy of transgene expression that have been incorporated into viral vectors. Thus, using a bispecific conjugate approach for direction of adenoviruses to ACE, we achieved dramatically (20-fold) enhanced pulmonary gene delivery and expression in vivo along with significantly reduced (five-to eight-fold) transgene expression in non-targeted organs in rats. 15 Moreover, the combination of transductional retargeting adenoviruses (via ACE) and transcriptional retargeting (with the use of an endothelial specific promoter for vascular endothelial growth factor receptor 1, flt-1) resulted in a remarkable (300 000-fold), highly synergistic improvement in selectivity of transgene expression for lung compared with the usual site of vector sequestration, the liver. 16 The antibody-directed lung-selective in vivo gene delivery system via ACE shows great potential in the rat. 15, 16 However, before this method can be applied to human clinical trials, this work must better approach the human condition. As recently reviewed by Donahue and Dunbar, 17 despite success in usual laboratory models on rodents and in vitro, 'the unique predictive value of nonhuman primate models … has become more apparent, and major advances in gene transfer efficiency have been made utilizing these powerful, but expensive and complex systems'. The distinctions between primates and rodents can dramatically impact on the predictive value of gene transfer trials in mice and rats for clinical applicability. 17, 18 The work presented here clearly bears this out.
Thus, this study focused on the ability of several mAbs directed against different epitopes of human ACE, to target lung endothelium in primates, and thus for delivery of transgenes to the pulmonary endothelium. This in vivo model performed in both rats and non-human primates should prove helpful in the pursuit of human clinical studies.
Results and discussion
Tissue and plasma ACE activity in primates This study was designed to develop an in vivo model for ACE-dependent drug/gene delivery to the pulmonary endothelium of primates. As we have previously demonstrated, anti-ACE mAb 9B9 specifically accumulates in the rat, hamster and cat lungs after systemic injection due to a high concentration of ACE in the lungs of these species. 11 However, data have not yet been described for ACE activity in tissues and blood of primates.
Data on ACE activity in plasma, lung and kidney of baboon (Papio anubis), macaques (Macaca arctoides, Macaca mulatta, Macaca fascicularis, Macaca nemestrina, Macaca assamensis, Macaca fuscata), cercopithecus (Cercopithecus aethiops), as well as chimpanzee (Pan troglodytes) are presented in Table 1 . ACE activity in the lung of these species was between three and eight times higher than in human, but between three and 10 times lower than in rat lung. It is likely that not only the absolute content of ACE in the lung, but also the gradient of ACE concentration from lung to blood (the organ/blood ACE ratio) determines the efficacy and selectivity of antibody lung accumulation.
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These data also show that the tissue/serum ACE activity ratio in non-human primates The plasma, kidney and lung tissues were prepared as described in Materials and methods. The plasma samples and supernatants containing solubilized ACE were used for ACE activity measurement using Z-Phe-His-Leu as ACE substrate. The data are presented as mean ± s.d., n = 3.
Gene Therapy was intermediate between human and rat. ACE activity was much higher in the kidney of studied animals relative to lung tissue or in serum. The observed high ACE level in the kidney appears to conflict with the absence of mAb 9B9 in kidney after in vivo antibody injection in all animals studied previously. [6] [7] [8] [9] [10] However, in the kidney, ACE is most highly expressed in the epithelium of proximal tubules and is found as well in brush border of intestine. 19 Thus, both of these areas are essentially inaccessible to monoclonal antibodies in circulation. [6] [7] [8] [9] [10] [11] [12] [13] It is likely that the large endothelial surface area, [20] [21] [22] and the consequent high ACE levels in the lung contributes to the selective accumulation of anti-ACE mAbs in the lung endothelium after systemic injection. [6] [7] [8] [9] [10] [11] [12] [13] Another contributing factor to this accumulation is the heterogeneous distribution of ACE in human and rat endothelial cells along the vascular tree. On average, only 10-20% of human and rat capillary endothelial cells in systemic circulation demonstrate ACE expression; whereas, virtually all endothelial cells in pulmonary capillaries strongly express ACE. 5, 6 This finding explains why among several anti-endothelial mAbs studied (ICAM-1 (CD-54), PECAM (CD-31), Thy.1.1 (CD-90), ACE (CD-143)), anti-ACE mAbs demonstrated the most selective lung accumulation after systemic injection. 6 The selectivity of ACE expression in the lung appears to be fairly ubiquitous across mammals, as we have observed a similar pattern of ACE expression in pulmonary versus systemic circulation across all 26 species tested, including human and non-human primates (Franke et al, in preparation) .
Therefore, the common cross-species character of endothelial ACE distribution pattern (Refs 5 and 6, and Franke et al, manuscript in preparation) and high ACE content in the lung of studied primates (Table 1) suggested that these species will also demonstrate lung endothelium targeting with anti-ACE mAbs.
Cross-reactivity of anti-human ACE mAbs with primates ACE
In order to choose the most suitable species for the development of the in vivo model of ACE-directed lung endothelial targeting on primates, we first estimated crossreactivity of a panel of 10 anti-human ACE mAbs with ACE from tissue and plasma of the primates, most widely used in biomedical experiments (Table 1) .
We have previously demonstrated that binding affinity of some anti-ACE mAbs greatly depends on the conformation of ACE. For example, the binding strength of mAbs i1A8 and 5F1 for ACE with hydrophobic transmembrane anchors was three-to five-fold higher than with soluble ACE, whereas mAb 3A5 binds more strongly with soluble ACE. 23, 24 Thus, we used both membrane-bound ACE (solubilized from the tissues by detergent and equilibrated to 20 mU/ml of ACE activity) and soluble ACE (from plasma, without hydrophobic transmembrane anchor, equilibrated to 2 mU/ml of enzymatic activity) to examine binding of the test antibodies.
The results of these experiments demonstrated that two mAbs, i2H5 and 5C5, directed toward almost identical epitopes, demonstrated high levels of binding with plasma and lung ACE from human, baboon, and all studied macaque species, but did not bind chimpanzee ACE ( Figure 1 ). Interestingly, both of these antibodies demonstrated essentially equal binding for both forms of ACE. In contrast, mAb 9B9 (previously studied mostly in rats) showed strong binding with ACE from human and chimpanzee (the most human-like primate) and very weak binding to ACE from other non-human primates. Moreover, mAb 9B9 did not precipitate macaque plasma ACE at 2 mU/ml at all, but did precipitate ACE from lung homogenates from all macaque species when tested at a higher concentration (20 mU/ml). These results indicate that the affinity of mAb 9B9 to macaque ACE is approximately two orders of magnitude (40-100-fold, depending on the species) lower compared with the affinity of mAb 9B9 for human ACE.
Although we have shown that mAb 9B9 accumulates selectively in the lungs of human volunteers and patients with sarcoidosis, 10 most of the other pre-clinical studies with this particular mAb have been performed using rats, where this antibody demonstrates strong selective accumulation in the lung. However, to bring this work to humans, it is clearly critical to examine non-human primates. This gap between laboratory small animals and humans could be filled with mAb I2H5 and 5C5, which demonstrated robust binding with ACEs from all nonhuman primates studied.
Lung targeting of the systemically injected anti-ACE mAbs
It is clear from our previous work and other publications that binding of mAb to ACE in solution does not guarantee the recognition of ACE by this particular mAb on the cell surface of capillaries in vivo, and subsequent selective accumulation in the lung. Our recent experiments indicate that binding of mAbs to ACE depends not only on the size of ACE (short, soluble ACE versus long ACE with transmembrane anchor), but also on the flexibility of ACE, in other words, on the availability of the epitope for a particular mAb in the circulation. For example, binding of mAb i1A8 with ACE (somatic two-domain ACE with transmembrane anchor) in solution was the lowest among the 10 studied mAbs to ACE, whereas binding of this antibody with ACE on the surface of CHO-ACE cells was the highest. 24 The fact that the efficacy of the endothelial targeting is epitope-dependent, was confirmed in the studies with another anti-endothelial mAbs. Thus, despite similar affinities, mAbs to different epitopes of PECAM-1 demonstrated pronounced difference in internalization after binding with endothelial cell surface and subsequently, in pulmonary uptake. 6 From four studied monoclonal antibodies, recognizing different rat lung endothelial antigens on tissue slices, Western blotting or in cultured cells, only two of them demonstrated selective pulmonary uptake. 25 Therefore, only in vivo experiments can confirm the feasibility of different anti-ACE mAbs for ACE-dependent, antibody-directed lung endothelium targeting.
Figure 1 Precipitation of ACE activity from tissue samples of different species by a panel of mAbs to ACE (cross-reactivity of anti-human ACE mAbs). (a) Precipitation of ACE activity from plasma of human, baboon (Papio anubis), bear macaques (Macaca arctoides), chimpanzee (Pan
Either mAb 9B9 or i2H5, or non-immune mouse IgG (control) was injected intravenously into stump-tail/Bear macaques (Macaca arctoides). To quantify the tissue distribution (and lung accumulation, in particular) of non-radiolabeled mAbs to ACE, we used a plate precipitation assay (see Materials and methods). The amount of mAbs accumulated in various organs was estimated indirectly by assaying the level of ACE activity, precipitated from tissue homogenates or plasma of studied animals to the plate, covered by anti-mouse IgG.
MAb i2H5, in agreement with in vitro results of the cross-reactivity with macaque ACE, demonstrated a substantial and selective accumulation in the lung. Moreover, and consistent with our previous results, 11 there was no detectable selective accumulation of i2H5 in kidney. Control mouse IgG did not accumulated in the lung, whereas mAb 9B9 demonstrated weak, albeit significant, accumulation in the lung (Figure 2) . The immunospecificity index (mAb/mIgG ratio) was 37 for mAb i2H5, but only 0.5 for mAb 9B9. Lung selectivity of i2H5 biodistribution (lung/blood ratio) was around 10.
The selectivity of antibody accumulation in the organ of interest (in our case in lung) greatly depends on the injected dose. 8 With the relatively modest dose of mAbs used in this experiment (0.1 mg/kg) lung selectivity is quite high. It is interesting to note that the i2H5/9B9 ratio of lung uptake in Macaca arctoides (Figure 2 ) was similar (above 30) to the i2H5/9B9 ratio in ACE binding from lung of these species-cross-reactivity in vitro experiments (Figure 1b) . Therefore, the relative in vivo lung accumulation of mAbs 9B9 and i2H5 in Macaca arctoides very precisely reflects their differences in binding affinity to ACE from this species. Despite the fact that affinity of mAb 9B9 to macaques ACE was much lower in comparison mAb i2H5, the selectivity of the mAb 9B9 accumulation in the lungs of macaques was still very high (see result of the gamma-imaging of lung uptake in macaque rhesus presented in Figure 3 ). This might be explained by the fact that binding affinity of mAb 9B9 with human ACE is very high -in the low picomolar range, 26 and even a significantly lower affinity of binding of mAb 9B9 with macaques ACE should still provide high selectivity of pulmonary endothelium targeting.
The internalization of an antigen or antigen-antibody complex, is one of the key determinants (along with intracellular trafficking and degradation) for successful gene transfer into the cell of interest, and into pulmonary endothelial cells in particular. Lung vascular immunotargeting has been demonstrated using antibodies to several different endothelial antigens, such as ACE, thrombomodulin, PECAM-1, ICAM-1, caveoli-associated antigens. 6, 27 However, many of these molecules have characteristics that suggest that they may not be ideal targets. Thus, poor internalization of ICAM-1 and PECAM-1 by endoGene Therapy 23 
Figure 2 The distribution of anti-ACE mAbs i2H5 and 9B9 in tissues of

). ACE activity precipitated from homogenates of the organs of monkeys, injected with non-immune mouse IgG (negative control), was subtracted from each value with specific, anti-ACE mAbs i2H5 and 9B9. (a) Precipitated ACE activity. The data represent the results of three independent experiments and expressed as mean ± s.d. (b) The 'immunospecificity' of the mAbs accumulation (estimated as the precipitation of ACE complexed with these mAbs) was also expressed as signal/background ratio.
thelium precludes intracellular delivery of a drug or genetic material. 27 However, in the case of PECAM-1, conjugation of anti-PECAM mAbs to streptavidin markedly facilitates pulmonary targeting and internalization of anti-PECAM mAbs. 6, 28 The situation with thrombomodulin is different: although endothelium internalizes antithrombomodulin mAbs, it undergoes rapid cellular degradation, 29 thus also precluding intracellular delivery, and possible its potential as gene transfer vector.
The mAbs to ACE are more suitable for intracellular delivery and possible gene transfer. Endothelial cells in culture, in perfused rat lungs and rat lungs in vivo internalized mAb 9B9 without significant intracellular degradation. 30 Both mAbs studied in the present paper (9B9 and i2H5) are also very effectively internalized by CHO cells, transfected with ACE cDNA. 24 However, these studies did not address the mechanism
Figure 3 Lung accumulation of radiolabeled mAb 9B9 in macaque rhesus (Macaca mulatta). Anterior thoraco-abdominal gamma-scintigrams shows localization of 111-In-anti-ACE mAb 9B9 (right) and non-immune mouse IgG (left) in macaque rhesus 1 h after i.v. injection of radiolabeled antibodies -200 g, 0.5 mCi. Background radioactivity was subtracted from each image. (Reprinted by permission of the Society of Nuclear Medicine from Ref. 7.)
of anti-ACE mAbs internalization by ACE-expressing cells. Very little is known about the internalization of ACE or ACE ligands, ACE recycling in the endothelial cells, or the effect of ACE ligands on ACE internalization. ACE is a transmembrane glycoprotein that is not considered (given our present knowledge) to possess receptor or signaling function. 30 The currently accepted pathway of ACE metabolism in the plasma membrane is its shedding to the extracellular medium. 31 A systematic study of ACE-antibody interaction on the surface of rabbit endothelial cells was performed in the laboratory of G Andres 32 using polyclonal antibodies to ACE. In a series of publications this group demonstrated that divalent polyclonal antibodies increased endothelial permeability via complement fixation.
Mabs to ACE, in contrast to polyclonal antibodies, does not induce complement-mediated injury to cultured endothelial cells. 11 No pathological changes were detected in organs of any animals studied, nor in human volunteers. 7, 8, 10, 11 The mechanism for internalization of mAbs to ACE still unclear. One possibility is that the ACE molecule undergoes constitutive turnover and recycling in the endothelial plasma membrane, like some other endothelial membrane proteins. 33, 34 If such constitutive ACE turnover occurs, ACE could serve as a carrier for intracellular transfer of anti-ACE mAbs bound to endothelial cells. The second possibility is that ACE itself is not normally internalized, but the interaction of mAbs to ACE induced internalization of the complex. 30 A similar mechanism might be responsible for the internalization of anti-PECAM mAbs: internalization of anti-PECAM I mAbs was very low, but dramatically facilitated by conjugation of mAbs to streptavidin. 28 However, regardless of the mechanism both mAbs to ACE-i2H5 and 9B9, internalized by endothelium, selectively accumulates in the lung of macaques after systemic injection and thus are candidates to be used for intracellular drug/gene delivery into the lung endothelium of studied non-human primates. 
and incubated (1 h, 4°C) for mAb binding assay (a) and 4 h at 37°C for ACE shedding assay (b). (a) mAb binding assay Bound anti-ACE mAbs were revealed with goat-anti-mouse IgG, conjugated with alkaline phosphatase. 24 (b) ACE shedding assay. The culture fluids were collected, centrifuged (for the precipitation of the detached cells) and the enzymatic activity of ACE, shed from the plasma membrane of cells, were measured as described in Materials and methods. Antibody-induced shedding (mAb i2H5 and 9B9) is expressed as % from the basal shedding of ACE (in the presence of control mouse IgG only). The data represent the results of several independent experiments and expressed as mean ± s.d.
Antibody-induced shedding of ACE from the cell surface
As discussed previously, the potential of mAb 9B9 to be used as a carrier for drug/gene delivery to the lung is somewhat limited in that this antibody has been shown to induce shedding of ACE from the plasma membrane of endothelial cells, both in vitro and in vivo conditions.
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In order to determine whether our other antibodies would have similar limitations, we compared the ACE shedding capacity of mAb i2H5 and 5C5 with that of 9B9. To do this, we incubated the antibodies with a CHO cell line that expresses ACE (clone 2C2), as well as with HUVEC. The results of this experiment (Figure 4) indicate that, while mAb i2H5 binds to ACE on the cell surface of CHO-ACE cells, this binding does not induce significant shedding of ACE from the plasma membrane. Binding to ACE (Figure 1 ) and the effect on ACE shedding for mAb 5C5 (not shown) was similar to that for mAb i2H5.
In contrast, mAb 9B9 induced ACE release at a rate that was more than twice (216%) the basal, constitutive rate of ACE release (Figure 4) . Shedding of ACE, increased by mAb 9B9 binding, was accompanied by weak, albeit significant loss of surface ACE (not shown). The same effect of 9B9 on ACE shedding (and the absence of similar effects for mAb i2H5) was demonstrated for HUVEC (not shown). The normal rate of the ACE shedding ranges between 5 and 15%/24 h depending on the cell-type, ie 5-15% of the amount of ACE on the cell membrane appeared in the culture medium after 24 h. 24, 35 This calculation explains, why a substantial increase in ACE shedding, induced by mAb 9B9 (two-fold in comparison with basal ACE shedding) leads to only a small loss of cell surface ACE. Moreover, there is indirect evidence of reappearance of ACE on the cell surface, suggesting the recycling of ACE. Our attempts to deplete ACE from the surface of cultivated human umbilical vein endothelial cells by repeated changing of the culture medium (every 4 h) resulted in shedding of the ACE to the culture medium in amounts greatly exceeding (several-fold) the amount of ACE remaining on the surface of these cultivated cells (Danilov et al, unpublished observation) . This experiment demonstrates that ACE shedded from the surface was very efficiently replaced by newly synthesized or recycled ACE. Taken together, the high level of mAb i2H5 binding to ACE-expressing cells in vitro, accumulation in the lung in vivo, and the absence of ACE shedding from the cell surfaces, indicate that this antibody has significant advantages over mAb 9B9 as a potential carrier for drug/gene delivery into the lung of primates, including humans.
Combined binding of mAbs to different, non-overlapping epitopes of ACE
The efficacy of targeted drug/gene delivery depends not only on the selectivity of targeting, but also on the absolute amount of drug or therapeutic gene that can be delivered to the site or organ of interest. In other words, the amount of the delivered agent should be therapeutically relevant. The results of this study demonstrate that mAb i2H5 bind to monkey ACE and accumulated in the lung after systemic injection. We have previously demonstrated that radiolabeled mAb 9B9 accumulates selectively (and safely) in the lungs of macaque rrhesus (Macaca mulatta) 7, 8 and human volunteers 10 after systemic injections. Thus, previous work, as well as the results of this study, suggest that mAb i2H5 and 5C5 will also accumulate selectively in human lung after systemic injection.
These findings may also allow for improved antibody redirecting of viral vectors. For example, we recently achieved substantial improvements in gene delivery to the rat pulmonary endothelial cells in vivo by using a bispecific conjugate (Fab-9B9) that redirected adenovirus infection away from its native receptor, CAR, towards ACE. 15 However, although this tropism modification significantly increased lung transgene expression (20-fold) and reduced liver and spleen transgene expression, residual transgene expression in these organs remained high in absolute terms, indicating the need for further improvements. The combination of transductional retargeting adenoviruses (via ACE) and transcriptional (with the use of an endothelial specific promoter) dramatically improved the selectivity of transgene expression for lung
Gene Therapy compared with the liver and spleen. Reporter gene expression in the lung becomes 200-300-fold more than in the liver and spleen even in absolute terms, thus achieving the improvement in relative selectivity 300 000-fold for the lung:liver ratio and 6000-fold for lung:spleen ratio when compared with untargeted vector. 16 Thus, in general, a high selectivity of gene delivery to the lung endothelium has been achieved, and the efficacy of transgene expression via ACE targeting becomes the next priority.
To examine means of improving transgene expression efficacy, we also studied whether the efficacy of drug/gene delivery to the pulmonary endothelium of human could be enhanced if we were to use a mixture of mAbs 9B9 and i2H5, both of which recognize human ACE (Figures 1 and 3 , this paper, and Refs 23 and 24), but are directed to different, non-overlapping epitopes. 23 Saturation of ACE binding for both mAbs i2H5 and 9B9 occurs at a concentration of approximately 1 g/ml, both with purified human kidney ACE adsorbed on plastic (Figure 5a ), as well as on the surface of ACE-expressing CHO cells (not shown). The mixture of these two mAbs at 1 g/ml revealed an additive character of binding to ACE (Figure 5b and c) . Additivity of mAb 9B9 and i2H5 binding was not complete however (Figure 5c ), probably due to the slightly different conformation of human ACE adsorbed on the plastic when compared with ACE anchored to the surface of CHO cells. Nonetheless, these results ( Figure 5 ) and recognition of monkey's ACE by both mAbs (see above) suggest that a mixture of mAbs i2H5 and 9B9 might substantially increase the efficacy of drug/gene delivery to the pulmonary endothelium in non-human primates models, as well as in future human clinical trials.
Therefore, selective accumulation of mAb i2H5 and 9B9 in primate lung after systemic administration, without any significant shedding of ACE from the cell surface (for mAb i2H5), suggests that non-human primates can serve as an in vivo model for ACE-dependent, anti-ACEdirected lung targeting and can fill the gap between rat models and future human clinical trials.
Materials and methods
The monoclonal antibodies (mAbs) against human lung ACE (9B9, 3A5, i1A8, 3G8, i2H5, 1G12, 6A12, 5F1) used in this study were described previously. 23 Two new mAbs -7A2 and 5C5 were raised against human kidney ACE by Pocard Ltd (Moscow, Russia).
ACE activity assay ACE activity in heparinized plasma (diluted 1:10-1:40 with PBS) was determined fluorimetrically with 5 mM Hip-His-Leu 36 or 2 mM of Z-Phe-His 37 as a substrate. The kidney and lung tissue samples were prepared by homogenization in 10 volumes of 50 mM Tris-HCL (pH 7.5) containing 150 mM NaCl and 0.5% Triton X-100. The homogenate was centrifuged 10 000 g for 10 min. The solubilized ACE remains in the supernatant.
ACE plate precipitation assay (cross-reactivity of anti-ACE mabs)
Ninety-six-well plates were coated with anti-ACE mAbs via anti-mouse IgG. 23 Wells were washed and then incubated with serum/plasma or tissue homogenates 24 The data represent the results of at least three independent experiments and expressed as mean ± s.d.
(sources of ACE) diluted in PBS/BSA, washed and assayed for plate-bound ACE activity using Hip-His-Leu as a substrate. 23 Animal care protocol Animal procedures were approved by the University of Illinois at Chicago Institutional Animal Care and Use Committees.
Antibody administration and in vivo biodistribution
The in vivo biodistribution of anti-ACE antibodies was performed as following. Male stump-tail/Bear macaques (Macaca arctoides) were anesthetized with ketamine (10 mg per kg) followed by pentobarbital injection (35 mg/kg). Subsequently mAbs to ACE (9B9 or i2H5) and control mouse IgG (1 mg/0.5 ml) were injected into cephalic vein. After 2 h, the animals were killed and blood and internal organs (washed in saline) were collected. Kidney and lung tissues were further processed for tissue homogenate preparation as described above. Quantification of tissue distribution of non-radiolabeled mAbs to ACE was performed using modified plate precipitation assay (see above and Ref. 23 ). The amount of mAbs accumulated in the monkey's organs was estimated indirectly, by assaying the level of ACE activity, precipitated from tissue homogenates or plasma of studied animals to the plate, covered by anti-mouse IgG. ACE from plasma or solubilized from the membrane of kidney or lung of the studied monkeys, binds to mAbs to ACE, accumulated in this particular organ after intravenous injection, and then quantitatively precipitated by polyclonal antibodies to mouse immunoglobulins, which where previously adsorbed to the microtiter plate.
ELISA Ninety-six-well microtiter plates were coated with 100 l of 1/50 dilution of purified human ACE (Chemicon, Temecula, CA, USA). mAbs (9B9 or i2H5) bound to the plate were quantified by goat-anti-mouse IgG, conjugated to alkaline phosphatase. 24 Cell ELISA CHO cells, transfected to express ACE-clone 2C2 24 or human umbilical vein endothelial cells (HUVEC, third passage) cultivated as described previously, 35 were grown in 96-well microtiter plates. These cell lines have been demonstrated to be a suitable in vitro model system to study anti-ACE antibody-dependent gene and drug targeting to the pulmonary endothelium. 15, 24 Cells were washed several times with PBS. Control mouse IgG or anti-ACE mAbs diluted in PBS/casein (0.2%) were added to the wells at concentrations of 0.1-10 g/ml and incubated for 1 h 37°C. Plates were washed and cells fixed with 4% buffered paraformaldehyde. Quantification of bound and unbound antibodies was determined by incubating the plates with alkaline phosphatase conjugated goat-anti-mouse IgG. 24 ACE shedding assay CHO-ACE cells (clone 2C2) or HUVEC, third passage, were grown in 96-wells plate until confluence. Then cells were washed and incubated with mAbs 9B9, i2H5, 5C5 or control mouse IgG (10 ug/ml in serum-free culture medium) for 4 h at 37°C. After that period, culture medium was harvested for ACE activity measurement. Cells, remaining on the plate after harvesting culture fluid were lysed with a detergent (CHAPS). ACE activity on the cell surface (lysates), as well as in the culture medium (released) was determined by the fluorimetric assay (see above) with Hip-His-Leu as a substrate. To determine correctly the effect of anti-ACE mAbs on the rate of ACE shedding (by referring ACE level in culture medium to that on the cell surface), we performed the following calculations. ACE activity which appeared in the culture medium of the cells incubated with nonimmune mouse IgG (basal, constitutive ACE shedding) was subtracted from that for the cells incubated with anti-ACE antibodies. The result of subtraction reflects antibody-induced appearance of ACE activity in the culture fluid, ie antibody-induced ACE shedding.
Neither mAb 9B9 nor mAb i2H5, which are directed to the N-terminal domain of ACE, inhibited ACE activity with substrate (Hip-His-Leu) which we used and which hydrolyzed mainly by C-terminal domain of ACE. 23 Therefore, mAbs themselves did not affect the shedding assay.
